ArticleWiener klinische Wochenschrift2025

PCSK9 inhibitors in real life-Cardiometabolic risk management in dyslipidemic patients in Vienna.

M Ferch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.